(4’-甲氧基-联苯-3-基)-乙酸 | 75852-49-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (4’-甲氧基-联苯-3-基)-乙酸
• 中文别名: 3-联苯-(4-甲氧基)乙酸；(4'-甲氧基-联苯-3-基)-乙酸
• 英文名称: 2-(4’-methoxy[1,1‘-biphenyl]-3-yl)acetic acid
• 英文别名: 3-(4-methoxyphenyl)phenylacetic acid；(1,1'-Biphenyl)-3-acetic acid, 4'-methoxy-；2-[3-(4-methoxyphenyl)phenyl]acetic acid
• CAS: 75852-49-2
• 化学式: C₁₅H₁₄O₃
• 分子量: 242.274
• InChiKey: VDSFTORZALGAEI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (4’-甲氧基-联苯-3-基)-乙酸 在 草酰氯 、 三(三甲代甲硅烷基)亚磷酸盐 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 苯 为溶剂， 反应 3.0h， 生成 [1-Hydroxy-2-[3-(4-methoxyphenyl)phenyl]-1-phosphono-ethyl]phosphonic acid
  参考文献：
  名称：

  Bisphosphonate Inhibition of the Exopolyphosphatase Activity of the Trypanosoma brucei Soluble Vacuolar Pyrophosphatase

  摘要：

  Trypanosoma brucei, the causative agent of African trypanosomiasis, contains a soluble, vacuolar pyrophosphatase, TbVSP1, not present in humans, which is essential for the growth of bloodstream forms in their mammalian host. Here, we report the inhibition of a recombinant TbVSP1 expressed in Escherichia coli by a panel of 81 bisphosphonates. The IC50 values were found to vary from similar to 2 to 850 mu M. We then used 3D QSAR (comparative molecular field and comparative molecular similarity index; CoMFA and CoMSIA) methods to analyze the enzyme inhibition results. The R-2 values for the experimental versus the QSAR-predicted activities were 0.78 or 0.61 for CoMFA and 0.79 or 0.68 for CoMSIA, for two different alignments. The root-mean-square (rms) pIC(50) error for the best CoMFA model was 0.41 for five test sets of five activity predictions, which translates to a factor of similar to 2.6 error in IC50 prediction. For CoMSIA, the rms pIC(50) error and error factors were 0.35 and 2.2, respectively. In general, the most active compounds contained both a single aromatic ring and a hydrogen bond donor feature. Thirteen of the more potent compounds were then tested in vivo in a mouse model of T. brucei infection. The most active compound in vivo provided a 40% protection from death with no apparent side effects, suggesting that further development of such compounds may be of interest.

  DOI：

  10.1021/jm058220g
• 作为产物：
  描述：

  Methyl 2-[3-(4-methoxyphenyl)phenyl]acetate 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 1.0h， 以78%的产率得到(4’-甲氧基-联苯-3-基)-乙酸
  参考文献：
  名称：

  非甾体抗炎药。2.具有抗炎和止痛活性的4′，5-二取代的3-联苯基乙酸及其衍生物的合成。

  摘要：

  制备了一系列5'，5-二取代的3-联苯基乙酸（5a-n）和几种α-甲基衍生物（5o-v）作为新开发的非甾体类抗炎药5'-氯-5-甲氧基-的类似物3-联苯基乙酸[1（DKA-9），R = 4-ClPh; R'= Me]，并使用角叉菜胶大鼠爪水肿和AcOH扭体试验评估抗炎和止痛活性。其中，5-氟-3-联苯基乙酸（5m）具有最高的抗炎活性，而2-（3-联苯基苯基）丙酸（5o）具有最高的止痛活性。但是，在这些测定中，它们的效力不及1（R = 4-C1Ph; R'= Me）。

  DOI：

  10.1021/jm00133a010

文献信息

• NOVEL COMPOUNDS WITH THYMINE SKELETON FOR USE IN MEDICINE
  申请人：TECHNISCHE UNIVERSITÄT DRESDEN

  公开号：US20210130328A1

  公开（公告）日：2021-05-06

  The present invention relates to novel compounds as new chemical entities with thymine skeleton, these compounds for use as in medicine, especially in the treatment of carcinoma, HSP27-associated diseases and cystic fibrosis; and a pharmaceutical product containing at least one of these compounds. Finally, a method of production of that novel compounds is presented. General formula of these compounds is formula (I): as further defined in claim 1.

  本发明涉及一种新型具有胸腺嘧啶骨架的化合物，这些化合物用于医药领域，特别是用于治疗癌症、HSP27相关疾病和囊性纤维化；以及含有至少一种这些化合物的药物产品。最后，提供了一种生产这些新型化合物的方法。这些化合物的一般化学式为式(I)，如权利要求书中进一步定义。
• PHARMACEUTICAL COMPOSITION AND METHOD
  申请人：Slade Rachel M.

  公开号：US20090155903A1

  公开（公告）日：2009-06-18

  The invention provides compounds, pharmaceutical compositions and methods for the therapeutic treatment and prevention of neurodegenerative disorder and other Aβ 42 -related diseases and disorders.

  该发明提供了化合物、制药组合物和方法，用于治疗和预防神经退行性疾病和其他与Aβ42相关的疾病和障碍。
• Enantiodivergent Functionalization of Aryl Alkenes into Diverse Biarylalkanoic Acids by Integrating Biocatalytic Cascades with Chemocatalysis
  作者：Willy W. L. See、Zhi Li

  DOI：10.1021/acscatal.3c03456

  日期：2023.10.20

  concept was successfully demonstrated through the enantiodivergent synthesis of 12 structurally diverse (S)- and (R)-2-biarylpropanoic acids (94–97% ee; up to >99% conversion) from easily available aryl alkenes by engineering epoxidation–isomerization–oxidation biocascades containing enantio-complementary enzymes and combining with Pd-catalyzed cross-coupling. The enzyme-chemical strategy was extended

  化学酶反应在不对称合成方面受到了极大的关注，但大多数报道的系统仅使用一步或两步酶反应进行相对简单的功能化，并且基于化学酶序列，该序列受到酶底物范围的限制。在此，我们报告了“多酶级联─化学催化”概念，通过酶-化学序列，通过整合多步生物级联引入功能性和对映选择性，对简单底物进行复杂的不对称功能化，并通过强大的化学催化使产品范围多样化。通过环氧化-异构化工程，从容易获得的芳基烯烃中对映异构合成12 种结构不同的 ( S )- 和 ( R )-2-联芳基丙酸（94–97% ee；高达 >99% 转化率） ，成功证明了这一概念–含有对映体互补酶并与 Pd 催化交叉偶联结合的氧化生物级联。酶化学策略扩展到 NSAID 药物 ( S )-氟比洛芬、( S )-酮洛芬和联苯乙酸的高产合成。这一概念能够简化每种类型的催化剂单独或化学酶序列无法实现的合成路线。
• COMPOUNDS WITH THYMINE SKELETON FOR USE IN MEDICINE
  申请人：Technische Universität Dresden

  公开号：EP3819006A1

  公开（公告）日：2021-05-12

  The present invention relates to novel compounds as new chemical entities with thymine skeleton, these compounds for use as in medicine, especially in the treatment of carcinoma, HSP27-associated diseases and cystic fibrosis; and a pharmaceutical product containing at least one of these compounds. Finally, a method of production of that novel compounds is presented. General formula of these compounds is formula (I): as further defined in claim 1.

  本发明涉及作为具有胸腺嘧啶骨架的新化学实体的新型化合物，这些化合物可用于医药，特别是治疗癌症、HSP27 相关疾病和囊性纤维化；以及含有至少一种这些化合物的医药产品。最后，还介绍了一种生产这种新型化合物的方法。 这些化合物的通式为式（I）： 如权利要求 1 所进一步定义。
• Compounds with thymine skeleton for use in medicine
  申请人：TECHNISCHE UNIVERSITÄT DRESDEN

  公开号：US11214564B2

  公开（公告）日：2022-01-04

  The present invention relates to novel compounds as new chemical entities with thymine skeleton, these compounds for use as in medicine, especially in the treatment of carcinoma, HSP27-associated diseases and cystic fibrosis; and a pharmaceutical product containing at least one of these compounds. Finally, a method of production of that novel compounds is presented. General formula of these compounds is formula (I): as further defined in claim 1.

  本发明涉及作为具有胸腺嘧啶骨架的新化学实体的新型化合物，这些化合物可用于医药，特别是治疗癌症、HSP27 相关疾病和囊性纤维化；以及含有至少一种这些化合物的医药产品。最后，还介绍了一种生产这种新型化合物的方法。 这些化合物的通式为式（I）： 如权利要求 1 所进一步定义。